• Cresco Labs posted first-quarter revenue of USD 151 million, down from USD 165.76 million a year earlier, while net loss widened to USD 17.01 million from USD 15.23 million.
• Operating income slipped to USD 11.17 million from USD 13.59 million, while adjusted EBITDA fell to USD 32.9 million from USD 36.23 million.
• Cash, cash equivalents, and restricted cash ended quarter at USD 67 million, down from USD 162.12 million a year earlier.
• Subsequent to quarter-end, Cresco was conditionally awarded a Texas Compassionate Use Program license, opened two Ohio dispensaries, and began supporting operations of nine Pennsylvania dispensaries under a management services agreement.
• Management said medical marijuana’s move from Schedule I to Schedule III is expected to eliminate Section 280E for Cresco’s medical operations, with a broader rescheduling hearing set for June 29, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cresco Labs Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605080630BIZWIRE_USPR_____20260507_BW583575) on May 08, 2026, and is solely responsible for the information contained therein.